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Abstract Ca2+ released from intracellular Ca2+ stores is
shown to be involved in pacemaker activity in the sino-atrial
(SA)-node. However, little is known about the molecular iden-
tity of the Ca2+ release channel/ryanodine receptor (RYR) in-
volved in pacemaker activity. We examined the mRNA distri-
bution of three di¡erent RYR isoforms (RYR1, RYR2, and
RYR3) in the mouse SA-node. RNase protection assay and in
situ hybridization revealed that RYR2 mRNA expresses widely
in the heart including the SA-node, while RYR3 mRNA expres-
sion is limited to the SA-node and to the right atrium. Thus, not
only RYR2 but also RYR3 may participate in pacemaker ac-
tivity.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Ryanodine receptors (RYRs) are a family of Ca2þ release
channels located in the sarcoplasmic and endoplasmic reticu-
lum (SR/ER) of various excitable or non-excitable tissues, and
play a crucial role in muscle contraction and Ca2þ signaling
[1^3]. Three RYR isoforms are identi¢ed in mammalian tis-
sues. RYR1 is predominantly expressed in skeletal muscle,
and RYR2 in the heart and brain, while RYR3 is expressed
at a relatively low level in various tissues including the brain,
diaphragm, and smooth muscle [4^6]. In cardiac muscle,
RYR2 contributes to Ca2þ-induced Ca2þ release, and under-
lies the mechanism of cardiac excitation^contraction coupling
[7].
Accumulating data using patch clamp experiments and con-
focal imaging of intracellular Ca2þ movement suggest that
Ca2þ release through RYR on SR membrane is a critical
factor in cardiac pacemaking, even though there is still con-
troversy about the extent of its contribution to pacemaker
activity. It is postulated that Ca2þ released from SR activates
inward Naþ-Ca2þ exchanger current, which in turn helps to
generate the pacemaker depolarization [8]. Stimulation of
L-adrenergic receptor (L-AR) is an important modulator of
cardiac beating, and regulation of RYR function by L-AR
appears to be involved in the autonomic regulation of heart
beating [9]. Despite these intriguing ¢ndings and exciting de-
bates on the role of RYR in pacemaking, little is known about
the molecules involved in the pacemaker activity in the sino-
atrial (SA)-node. RYR2 is predominantly expressed in the
heart including the SA-node, but it is not tested whether other
RYR isoforms are expressed in the SA-node or not. To ad-
dress these questions, we performed RNase protection assay
and in situ hybridization to determine the mRNA expression
of three RYR isoforms in the SA-node region.
2. Materials and methods
2.1. RNase protection assay
RNase protection assays were performed as described previously
[10]. Total RNA from adult ICR mouse tissues was puri¢ed by
acid-guanidine-thiocyanate-chloroform extraction methods. The
probes were synthesized from pGEM1 vectors containing the indi-
cated fragments of the following mouse RYR cDNAs: RYR1, Gen-
Bank accession number X83932, bp 1286^1503; RYR2, AF295105,
bp 14519^14897; RYR3, D38218, bp 364^689. RYR1, RYR2, and
RYR3 fragments were obtained by reverse transcription-polymerase
chain reaction (RT-PCR) from skeletal muscle, left ventricle and
brain, respectively. The plasmid vectors were linearized with NdeI
or BglII. Antisense RNA probes were transcribed with T7 RNA poly-
merase in the presence of [K-32P]uridine triphosphate (UTP) (Amer-
sham Biosciences) using the Ambion RPA III Kit (Ambion). After
puri¢cation, 8U104 counts per minute (cpm) of cRNA probe were
hybridized with the total RNA, and incubated with RNase A/RNase
T1 mix and RNase digestion bu¡er. Subsequently, RNase inactivation
bu¡er was added and incubated at 320‡C for 15 min. Samples were
obtained after centrifugation, and analyzed on 6% acrylamide gels
containing 8 M urea in 0.5UTBE solutions. Autoradiographs were
exposed for 1 day at room temperature for RYR1 and RYR2, and for
3 days at 380‡C for RYR3.
2.2. In situ hybridization
In situ hybridization analysis was performed as described previously
[11]. The same linearized probes as were prepared for protection assay
were used for in situ hybridization. Antisense RNA probes were tran-
scribed with T7 or SP6 RNA polymerase (Invitrogen) in the presence
of digoxigenin RNA labeling mix (Roche). Hybridization was carried
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out overnight at 55‡C using digoxigenin-dUTP labeled probes. After
washing and treatment with RNase, signals were detected by using an
anti-digoxigenin-alkalinephosphatase-conjugated antibody (Roche).
Nitroblue tetrazolium formulation (Invitrogen) and 5-bromo-4-
chloro-3-indolyl-phosphate formulation (Invitrogen) were used for
staining.
2.3. Action potential recording
The microelectrode study was performed as described previously
[12]. Adult ddy mice were exsanguinated and the heart was quickly
removed. Tissues, including the SA-node, were cut perpendicularly to
the crista terminalis. Preparations were pinned down horizontally on a
silicon block in an organ bath ¢lled with oxygenated (95% O2 and 5%
CO2) physiological salt solution of the following composition (in
mM): NaCl, 118.4; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; NaHCO3,
24.9; and glucose, 11.1 (pH 7.4). The temperature of the organ
bath was maintained at 32‡C. Action potentials were recorded with
glass microelectrodes ¢lled with 3 M KCl having resistance of 50^80
M6. The output of the microelectrode ampli¢er (MEZ-8201, Nihon
Kohden, Tokyo, Japan) was monitored through a dual beam cathode
ray oscilloscope (VC-11, Nihon Kohden, Tokyo, Japan) and fed in to
an AD converter (Analog Pro, Canopus, Kobe, Japan) attached to a
computer (PC9801RA, NEC, Tokyo, Japan) for analysis. The action
potential parameters measured were cycle length (CL), maximum dia-
stolic potential (MDP), overshoot (OS), action potential amplitude
(AMP), maximum rate of rise (+Vmax), and action potential duration
at 50% amplitude (APD50).
Signi¢cance of di¡erence between means was evaluated by paired
t-test. A P-value less than 0.05 was considered statistically signi¢cant.
Ryanodine was purchased from Wako (Japan) and dissolved in water.
3. Results
3.1. E¡ects of ryanodine on the action potential of
SA-nodal tissues
To investigate whether Ca2þ release through RYR is in-
volved in pacemaker activity, we examined the e¡ects of rya-
nodine on the action potential con¢gurations of mouse SA-
node tissue. Typical traces in the absence and presence of
30 nM ryanodine are shown in Fig. 1. The meanRS.E.M.
of control action potential parameters from three preparations
were: CL, 235R 22 ms; MDP, 356.7R 2.6 mV; OS, 7.9 R 1.0
mV; AMP, 64.4 R 3.1 mV; APD50, 46.9R 4.8 ms; +Vmax,
11.6 R 1.5 V/s. In the presence of 30 nM ryanodine the values
of each parameter were: CL, 278R 33 ms; MDP, 351.8R 2.3
mV; OS, 5.1 R 1.1 mV; AMP, 58.5 R 3.3 mV; APD50,
56.4R 6.4 ms; +Vmax, 6.3 R 0.5 V/s. Thus, CL prolonged by
24.3R 1.3%, APD50 by 17.2R 7.4%, while +Vmax decreased by
29.9R 1.7%. MDP, OS, and AMP were not signi¢cantly
changed. Ryanodine also reduced the late phase of pacemaker
potential (Fig. 1). These observations demonstrate that RYR
a¡ects pacemaker activity in the mouse SA-node, which is
consistent with previous studies [13^15].
3.2. RYR2 is expressed in the SA-node and other regions of
the heart
To demonstrate the expression of RYRs in the SA-node, we
carried out RNase protection assays and in situ hybridization
analyses. Fig. 2a shows that RYR2 expression was observed
in the SA-node as well as in other regions of the heart. After
normalization using the glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) signal, the RYR2 expression in di¡erent
regions of the heart is slightly higher in right atrium and
ventricle than in the left atrium and ventricle (Fig. 2b). After
in situ hybridization, intense staining with the antisense
RYR2 probe was detected both in the SA-node and in atrial
tissues, which is consistent with those obtained by RNase
protection assay (Fig. 2c). No signi¢cant signal was detected
with the sense RYR2 probe that was used as a negative con-
trol.
3.3. RYR3 is expressed in the SA-node and right atrium
We employed the same approaches to examine the expres-
sion of RYR3 in the SA-node. Fig. 3a shows that RYR3
signals were clearly detected in the SA-node, right atrium,
and brain. A faint signal was also detected in the right ven-
tricle. After in situ hybridization analysis, the RYR3 antisense
probe exhibited signals in the SA-node regions and right at-
rium, whereas the sense probe that was used as a negative
Fig. 1. E¡ects of ryanodine on action potential of mice SA-node.
Typical action potential traces obtained in the absence and presence
of 30 nM ryanodine.
Fig. 2. RYR2 mRNA expression in mouse cardiac tissue. a: RNase
protection analysis of RNAs from various regions of mouse heart.
RYR2 probes were hybridized with 5 Wg of total RNA from yeast
tRNA, 0.5 or 1 Wg of total RNA from left and right ventricle, left
and right atrium, and 1 Wg of total RNA from SA-node. As an in-
ternal control, GAPDH probe was also included in each sample.
b: Quanti¢cation of RYR2 mRNA after normalization to GAPDH
RNA. c: In situ hybridization of mice SA-node regions and right
atrial myocardium with sense and antisense RYR2 cRNA probes.
Antisense RYR2 probe hybridized with SA-node (right upper pan-
el), and right atrium (right lower panel) samples, while no hybridi-
zation signals were detectable in the samples with sense probes.
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control did not reveal any staining in these tissues (Fig. 3c).
These results con¢rm that RYR3 is expressed both in the SA-
node and in the right atrium. RYR3 expression was not de-
tected in the left ventricle or atrium under the present exper-
imental conditions (Fig. 3a).
3.4. RYR1 is not expressed in the SA-node or other regions of
the heart
We also examined the expression of RYR1 in the SA-node
and other regions of the heart. Using RNase protection as-
says, we detected RYR1 expression in skeletal muscle, but not
in the SA-node, atrium, or ventricle (Fig. 4). In the same
experiment, probes for RYR2 and RYR3 showed a similar
expression pattern to that described above (Figs. 2 and 3).
The corresponding protected fragments of the RYR1,
RYR2, and RYR3 probes were not detected in the yeast
tRNA, further con¢rming the speci¢city of the RNase protec-
tion assays.
4. Discussion
The presence of RYR2 in the SA-node has been demon-
strated by immunohistochemical labeling and functional anal-
ysis [16,17]. In the present study, we provide the ¢rst evidence
that RYR3 in addition to RYR2 is expressed in the mouse
SA-node (Figs. 2 and 3).
Although SR Ca2þ release is involved in pacemaking activ-
ity, it is still controversial how much extent it contributes to
the pacemaking activity. Lakatta et al. [18] suggested that SR
Ca2þ release might be obligatory for pacemaking, because
30 mmol/l ryanodine abolishes the spontaneous activity of
isolated SA-node cells from rabbit. On the other hand, Honjo
et al. [19] showed that 30 mmol/l ryanodine slowed sponta-
neous rate only by about 20% in the same species, and ques-
tion the dominant role of SR Ca2þ release in pacemaking.
Embryonic stem (ES) cells exhibited spontaneous beating after
they di¡erentiate into cardiac cells. RYR2 knockout ES cells
displayed spontaneous beating with a slower rate than that of
the wild-type ES cells did [20], indicating that RYR2 partially
contributes to the pacemaker activity. However, these data do
not resolve the controversy, because it is not known whether
RYR2 is the only RYR expressed in the SA-node. In fact, in
the present study we found that not only RYR2 but also
RYR3 expressed in the SA-node. It is of worth, therefore,
to test the e¡ects of RYR2 and RYR3 double knockout on
the pacemaking.
What is the rationale for the coexistence of RYR2 and
RYR3 in the SA-node? RYR2 and RYR3 might function in
a complementary manner to each other, or they might have
their distinct functions. In rat heart, expression levels of
RYR2 and RYR3 mRNA di¡er regionally and vary develop-
mentally [21]. Thus, it is possible that RYR2 and RYR3 ex-
press in di¡erent regions of the heart or even of the SA-node,
or in the di¡erent developmental stages of the SA-node. Thus,
they have distinct functions in a region- or an age-speci¢c
manner. Interestingly, RYR2 is expressed in various regions
of the heart, while RYR3 expression is mainly detected in the
SA-node and right atrium (Fig. 3). Consistent with these ¢nd-
ings, RYR3 has been shown to localize primarily in the con-
duction system of the ventricle [22]. Thus, RYR3 may have a
unique role in rhythm generation and conduction.
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Fig. 3. RYR3 mRNA expression in mouse cardiac tissue. a: RNase
protection analysis of RNAs from various regions of mouse heart.
RYR3 probe was hybridized with 5 Wg of total RNA from yeast
tRNA, 1 Wg of total RNA from left and right ventricle, left and
right atrium, or SA-node, and 5 Wg of total RNA from whole brain.
b: Quanti¢cation of RYR3 mRNA after normalization to GAPDH
RNA. c: In situ hybridization of mice SA-node regions and right
atrial myocardium with sense and antisense RYR3 cRNA probes.
Antisense RYR3 probe hybridized with SA-node (right upper pan-
el), and right atrium (right lower panel) samples, while no hybridi-
zation signals were detectable in the samples with sense probes.
Fig. 4. RYR1 mRNA expression in mouse cardiac tissues. Total
RNA from mouse cardiac tissues (left and right ventricle, left and
right atrium, SA-node), skeletal muscle and brain were analyzed by
RNase protection. RYR1, RYR2, RYR3, and GAPDH probes were
hybridized with 5 Wg of total RNA from yeast tRNA 0.5 or 1 Wg of
total RNA from left and right ventricle, left and right atrium, 1 Wg
of total RNA from SA-node, 5 Wg of total RNA from skeletal
muscle, and 5 Wg of total RNA from brain.
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